Therapeutic Solutions
International, Inc. Announces the Appointment of Francesco M
Marincola, MD, FACS, to the TSI Scientific Advisory
Board
Oceanside, CA -- October 21, 2015 -- InvestorsHub NewsWire --
Therapeutics Solutions International, Inc., (OTC
Markets:TSOI) announced today that Francesco M
Marincola, MD, FACS, has been appointed to our Scientific Advisory
Board.
Dr. Marincola previously held the position of Chief of the
Infectious Disease and Immunogenetics Section (IDIS) and Tenured
Senior Investigator at the U.S. National Institutes of Health
(NIH). He was also Director of the Immunogenetics Program,
Department of Transfusion Medicine, Director of the Federation of
Clinical Immunology Societies (FOCIS) Center for Excellence and
Co-Director of the Trans-NIH Center for Human Immunology.
Dr. Marincola received his MD summa cum laude from the
University of Milan and his surgery training from Stanford
University. Dr. Marincola is the second most cited scientist in the
field of melanoma during the last ten years, with 55 papers cited
3,704 times to date. His research interest is primarily
translational and focuses on the development of strategies for the
dynamic study of patients response to therapies. His approach has
deepened understanding of the mechanisms leading to rejection of
tumors, allograft, graft versus host disease and leading to the
development of autoimmunity.
With the appointment of Dr. Marincola to our Scientific Advisory
Board who now joins Dr. Michael G. Agadjanyan, Dr. Santosh Kesari,
and Dr. Harry Lander, we truly have a world class team of
scientists to identify and discuss significant emerging regulatory,
research and scientific issues and trends and competitive activity,
including their potential impacts on any Company programs, plans,
or policies relating to its development programs and research
activities said Timothy Dixon, President and CEO of Therapeutic
Solutions.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION